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Abstract
Background: The aim of this study was to investigate the effect of intravitreal anti-vascular endothothelial growth
factor (VEGF) injection on intraocular pressure (IOP) and mean ocular perfusion pressure (MOPP).
Methods: MOPP results were obtained by measuring mean arterial pressure (MAP) and IOP just before the
injection, immediately after the injection, at 30 min, 1 day, and 1 week after injection from 65 eyes of 42 patients.
Results: Pre-injection mean IOP was 16.66 ± 3.50 mmHg, and mean IOP was 43.81 ± 9.69 mmHg immediately
after the injection, 17.57 ± 4.44 mmHg at 30 min, 15.00 ± 4.21 mmHg at 1 day, and 15.90 ± 3.63 mmHg at 1 week
after the injection. Pre-injection mean MOPP was 46.39 ± 5.78 mmHg, and mean MOPP was 25.14 ± 8.79 mmHg
immediately after the injection, 45.87 ± 6.31 mmHg at 30 min, 46.93 ± 6.25 mmHg at 1 day, and 46.50 ± 4.94 mmHg at
1 week after the injection.
Conclusion: The instant increase in IOP by intravitreal anti-VEGF injection led to a transient decrease in MOPP.
Based on this finding, the instant increase in IOP after intravitreal anti-VEGF injection does not significantly impair
retinal blood flow.
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Background
Intravitreal injection is an excellent method for delivering
drugs for various vitreoretinal diseases, the incidences of
which are increasing globally every year. Various vitreoret-
inal diseases such as choroidal neovascularization due to
exudative age-related macular degeneration, diabetic macu-
lar edema, and macular edema due to retinal vein occlusion
are treated with anti-vascular endothelial growth factors
(VEGF) such as ranibizumab (Lucentis®) and bevacizumab
(Avastin®). Thus, expansion of the use of intravitreal anti-
VEGF is expected.
The volume of the intravitreal injection can directly
increase the intraocular pressure (IOP) and thereby
negatively affect the retinal and optic nerve blood sup-
ply. Animal experiments show that an acute rise in IOP
blocks axonal transport to the optic nerve head, and
damage to the optic nerve is directly proportional to
the rise in IOP [1]. An acute rise in IOP also decreases
juxtapapillary retinal and optic nerve head blood flow
proportional to the quantitative rise in IOP [2].
There are many reports about safe levels of an increase
in IOP after intravitreal anti-VEGF injection [3–7]. Stud-
ies of Lucentis® (ranibizumab, Genentech Inc./Roche,
South San Francisco, CA. USA) revealed that there was
no long-term change in IOP over 2 years of follow-up
[8]. IOP increased during the first hour post-injection
and then dropped within 60 min to only 2 to 3 mmHg
higher than the baseline level. This study also reported
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that at 1 h post-injection, 18 % of patients had an IOP of
30 mmHg or higher. The report on escalating doses of
Lucentis showed no changes in IOP for up to 4 months
of follow-up [9].
Avastin® (bevacizumab, Novartis/Genentech Inc., CA.
USA) is a drug used off-label for intravitreal treatment
of various retinal diseases. A previous report on the
levels of post-injection IOP demonstrated that intravit-
real Avastin causes a volume-related increase in IOP that
does not occlude the central retinal artery. The IOP fell
below 30 mmHg in all selected eyes within 15 min [5].
Although previous studies focused on the rise in
post-injection IOP, substantially the entire blood supply
of the retina and optic nerve head is affected by ocular
perfusion pressure, which means that ocular perfusion
pressure is more important than IOP. Mean ocular per-
fusion pressure (MOPP) is defined as the difference
between the mean ophthalmic artery pressure and IOP
[10]. Clinical measurement of the mean pressure of the
ophthalmic artery, however, is quite difficult. The mean
ophthalmic artery pressure can be estimated by using a
value of two-thirds of the mean blood pressure (MBP)
of the brachial artery measured in a seated position
[11]. Therefore, in the present study, we defined the
MOPP as the difference between 2/3*MBP of the bra-
chial artery and IOP [10]. The normal range of MOPP
is 40 mmHg to 55 mmHg.
A volume-related IOP increase due to intravitreal anti-
VEGF injection will decrease the MOPP and negatively
affect the retina and optic nerve head blood supply. The
purpose of this study was to analyze the short-term
change in IOP and MOPP after intravitreal anti-VEGF
injection, and to evaluate the safety of the procedure.
Methods
This study was a prospective case series of consecutive
patients undergoing intravitreal injection of anti-VEGF
at the Eulji Medical Center, Seoul, Korea from October
2011 to November 2011. Patients were asked to partici-
pate if they were over 20 years of age and were able to
have a regular follow-up. To maximize generalizability,
exclusion criteria were kept to a minimum. Patients who
had intravitreal injections of triamcinolone acetonide
any time up until 6 months prior to the study, patients
with active uveitis or ocular ischemic syndrome, and di-
agnosed with any type of glaucoma were excluded from
selection. According to these exclusion criteria, 103 eyes
of 67 patients were excluded from a total 168 eyes of
109 patients. But the patients participating in this study
would have undergone anti-VEGF intravitreal injection
even if they had not been enrolled.
The prospective clinical study was approved by the
Institutional Review Board (IRB)/Ethics Committee at
the Eulji Medical Center of Eulji University, Seoul,
Korea. Informed consent was obtained from each patient
prior to participation in the study. All procedures con-
formed to HIPAA regulations and the Declaration of
Helsinki for research involving human subjects.
Before intravitreal injection, patients signed a stand-
ard informed consent form describing the potential
risks and benefits of the procedure and consecutive
management, which included IOP and blood pressure
measurements.
The following basic tests were made on every subject
before going to operation room for intravitreal injection:
(1) best corrected visual acuity and IOP, (2) blood pres-
sure, (3) slit-lamp examination. Patients who had one of
the following conditions underwent the delayed proced-
ure: (1) systolic blood pressure (SBP) over 140 mmHg,
(2) diastolic blood pressure (DBP) over 90 mmHg, and
(3) IOP over 30 mmHg.
Intravitreal injections were performed by one surgeon
(Young Gyun Kim) using aseptic techniques in an oper-
ating room at an outpatient ophthalmology clinic. Pa-
tients were prepared and draped in a standard fashion
and positioned supine for the procedure. After applying
topical proparacaine for anesthesia, a lid speculum was
used for lid control, and the eyeball was sterilized with a
solution of 5 % povidone–iodine and irrigated with
sterile BSS. Intravitreal injection of Avastin (bevacizu-
mab, 0.05 mL) or Lucentis (ranibizumab, 0.07 mL) was
injected with a 30-guage needle through the inferotem-
poral or inferonasal pars plana 3.5 mm posterior to the
limbus. The needle was inserted approximately 1.0 cm
into the globe, and the injection was performed. After
injection, a sterile cotton swab was placed on the injec-
tion site to prevent reflux of the medicine or vitreous.
MBP and IOP values were obtained at baseline, immedi-
ately after the injection, and at 30 min, 1 day, and 1 week
after injection. The MBP of the brachial artery was mea-
sured with an automatic sphygmomanometer with the
patient in the sitting position, and the IOP was measured
in the same position with an Icare® PRO rebound tonom-
eter model (Icare, Tiolat Oy, Helsinki, Finland) by the
same examiner. MOPP was measured using the following
formula [12]. MOPP = 2/3 * [diastolic pressure + 1/3*(sys-
tolic pressure—diastolic pressure)]—IOP. Thus, MOPP
was calculated using the measured BP and IOP at each
time-point.
Statistical tests were performed using SPSS software
version 14.0 (SPSS Inc, Chicago, IL) The baseline values
and individual values of IOP and MOPP at each time-
point were analyzed using a paired t-test. Variable fac-
tors that can affect IOP and MOPP after intravitreal
injection—the difference in dosage (Avastin 0.05 mL,
Lucentis 0.07 mL) and the presence of post-injection
vitreous regurgitation—were set and each group was
analyzed using the Student’s t-test.
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Results
The data for 65 eyes of 42 patients were included in this
analysis. Table 1 shows the basic patient characteristics
and clinical data for the sample. Mean patient age was
59.7 ± 13.6 years. Classifying the patients by disease type
resulted in: 16 eyes (24.6 %) with diabetic macular
edema, 10 eyes (15.4 %) with proliferative diabetic
retinopathy-vitreous hemorrhage (a large majority had
diabetes mellitus (DM)-related disease), 15 eyes (23.1 %)
with exudative age-related macular degeneration, 14 eyes
(21.5 %) with retinal vein occlusion-related macular
edema, 8 eyes (12.3 %) with chronic central serous chor-
ioretinopathy, and 2 eyes (3.1 %) with idiopathic chor-
oidal neovascularization. Intravitreal injection of Avastin
(0.05 mL) or Lucentis (0.07 mL) was performed in 50 eyes
(76.9 %) or 15 eyes (23.1 %), respectively. Post-injection
vitreous regurgitation was confirmed in 11 (16.9 %) of 65
eyes.
Figure 1 shows the change in IOP beginning from the
value before the injection to the value of 4 post-
injection time points. Pre-injection mean IOP was
16.66 ± 3.50 mmHg, and it was 43.81 ± 9.69 mmHg im-
mediately after the injection, 17.57 ± 4.44 mmHg at
30 min, 15.00 ± 4.21 mmHg at 1 day, and 15.90 ±
3.63 mmHg at 1 week after the injection. Figure 2
shows the change in MOPP beginning from the value
before the injection to the value of 4 post-injection
time-points. Pre-injection mean MOPP was 46.39 ±
5.78 mmHg, and it was 25.14 ± 8.79 mmHg immedi-
ately after the injection, 45.87 ± 6.31 mmHg at 30 min,
Table 1 Demographic and Clinical Characteristics of the Study
Sample
Variable No. (%)
Sex (No. of patient)
Female 18 (42.9 %)
Male 24 (57.1 %)
Age, years (No. of patients)
20–59 21 (50.0 %)
60–69 10 (23.8 %)
70–79 9 (21.4 %)
80+ 2 (4.8 %)
Diagnosis (No. of eyes)
DME 16 (24.6 %)
PDR—vitreous hemorrhage 10 (15.4 %)
AMD/Wet type 15 (23.1 %)
RVO related ME 14 (21.5 %)
Chronic CSC 8 (12.3 %)
Idiopathic CNV 2 (3.1 %)
Drug (No. of eyes)
Bevacizumab (0.05 mL) 50 (76.9 %)
Ranibizumab (0.07 mL) 15 (23.1 %)
Postoperative vitreous regurgitation (No. of eyes)
Yes 11 (16.9 %)
No 54 (83.1 %)
DME diabetic macular edema, PDR proliferative diabetic retinopathy, AMD
age-related macular degeneration, RVO retinal vein occlusion, CSC central
serous chorioretinopathy, CNV choroidal neovascularization
Fig. 1 Short-term changes in intraocular pressure (IOP) after intravitreal Avastin or Lucentis injection. Compared to the pre-injection IOP values,
only those checked immediately after injection were significantly different
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46.93 ± 6.25 mmHg at 1 day, and 46.50 ± 4.94 mmHg at
1 week after the injection.
Only the IOP immediately after injection was signifi-
cantly different from the pre-injection IOP (Fig. 1, p <
0.001). Only the MOPP immediately after the injection
was significantly different from the pre-injection MOPP
value (Fig. 2, p < 0.001).
The IOP and MOPP recovered to their pre-injection
values within 30 min after injection. 98.5 % of the IOP
values recovered to less than 30 mmHg within 30 min
after injection (Table 2) and 87.7 % of MOPP values re-
covered to above 40 mmHg within 30 min after injection
(Table 3).
In addition, the patients were divided into two groups
according to the injection type (0.05 mL Avastin or
0.07 mL Lucentis) and their IOP and MOPP values imme-
diately after injection were analyzed. We also evaluated
the presence of post-injection vitreous regurgitation. The
mean IOP of the Avastin group was 41.72 ± 9.74 mmHg
and that of the Lucentis group was 45.15 ± 9.65 mmHg.
The mean MOPP of the Avastin group was 26.81 ±
8.68 mmHg and that of the Lucentis group was 24.27 ±
8.51 mmHg. IOP and MOPP values were not significantly
different between the Avastin group and Lucentis group
(Table 4, p > 0.05).
Mean IOP was 39.92 ± 9.12 mmHg in the group with
post-injection vitreous regurgitation and 44.68 ± 9.27 mmHg
in the group without post-injection vitreous regurgita-
tion. Mean MOPP was 28.83 ± 9.56 mmHg in the group
with post-injection vitreous regurgitation and 24.48 ±
8.27 mmHg in the group without post-injection vitre-
ous regurgitation. Post-injection vitreous regurgitation
did not significantly change mean MOPP and IOP
(Table 5, p > 0.05).
Fig. 2 Short-term changes in mean ocular perfusion pressure (MOPP) after intravitreal Avastin or Lucentis injection. Compared to the pre-injection
MOPP values, only those checked immediately after injection were significantly different




Baseline Immediately 30 min 24 h 1 week
0–9 1 (1.5 %) 1 (1.5 %) 2 (3.1 %)
10–19 54 (83.1 %) 42 (64.6 %) 59 (90.8 %) 59 (90.8 %)
20–29 10 (15.4 %) 5 (7.7 %) 21 (32.3 %) 4 (6.1 %) 6 (9.2 %)
30–39 15 (23.1 %) 1 (1.5 %)
40–49 22 (33.8 %)
50–59 20 (30.8 %)
60–69 3 (4.6 %)
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Discussion
As intravitreal anti-VEGF injection becomes a more
common treatment modality for various vitreoretinal
diseases, there is increased concern regarding acute IOP
elevation after intravitreal injection in relation to the
acute increase in volume inside the eye. Several studies
have examined post-injection IOP spikes and most re-
vealed that IOP spikes are transient and additional inter-
vention to lower the IOP, such as anterior chamber
paracentesis, is not necessary [4–9]. Previous studies fo-
cused only on the rise in post-injection IOP. The blood
supply to the retina and optic nerve head, however, is af-
fected more by a change in the ocular perfusion pressure
than by an increase in IOP. The present study is one of
the first studies to examine the decrease in MOPP that
occurs following intravitreal injection in addition to the
post-injection increase in IOP.
The blood supply to the retina and optic nerve head
is maintained by autoregulation, which means proper
microcirculation in these tissues is predicted to be
spared despite a sudden decrease in MOPP. There are
few studies of human eyes regarding this issue, but la
Cour et al conducted an experiment in porcine eyes
that revealed that microcirculation of the retina is
maintained regardless of a 10 to 20 mmHg decrease in
MOPP [13]. Additionally, Kyhn et al, in a study on por-
cine eyes, found that ischemic damage of the retina oc-
curred by decreased ocular perfusion pressure, and
concluded that maintaining MOPP at 5 mmHg for 2 h
can irreversibly damage retinal tissue [14].
In the present study, the mean difference between pre-
injection IOP and IOP immediately following the injec-
tion was 27.01 ± 9.88 mmHg. The mean difference
between pre-injection MOPP and MOPP just after injec-
tion was 21.25 ± 9.30 mmHg. The mean change in IOP
and MOPP 30 min after the injection compared to the
baseline IOP and MOPP were only 0.92 ± 3.44 mmHg
and -0.53 ± 4.94 mmHg, respectively. Therefore, recov-
ery of IOP and MOPP to the pre-injection values oc-
curred within 30 min after the injection. Furthermore,
no less than 10 mmHg of MOPP level was observed at
different time-points (Table 3). These results indicate
that intravitreal anti-VEGF injection is a safe treatment
modality because the blood supply to the retina and
optic nerve head was not impaired by the injection.
We assumed that the degree of change in post-injection
IOP and MOPP would be affected by the difference in the
injection dosage (0.05 mL Avastin, 0.07 mL Lucentis) and
by the presence of post-injection vitreous regurgitation.
These variables, however, had minimal effects on the dif-
ference in post-injection IOP and MOPP (Tables 4, 5).
This outcome is thought to be the result of the rela-
tively small sample size (65 eyes), the small difference
in the injection dosage (0.02 mL), and a low incidence
of post-injection vitreous regurgitation (11 eyes) due
to the use of a 30-gauge needle.




Baseline Immediately 30 min 24 h 1 week
0–9
10–19 14 (21.6 %)
20–29 30 (46.2 %) 1 (1.5 %) 2 (3.1 %) 5 (7.7 %)
30–39 9 (13.8 %) 19 (29.2 %) 7 (10.8 %) 1 (1.5 %) 43 (66.1 %)
40–49 36 (55.4 %) 1 (1.5 %) 35 (53.8 %) 39 (60.0 %) 15 (23.1 %)
50–59 18 (27.7 %) 1 (1.5 %) 22 (33.8 %) 22 (33.8 %) 2 (3.1 %)
60–69 2 (3.1 %) 1 (1.5 %)
Table 4 Intraocular Pressure (IOP) and Mean Ocular Perfusion
Pressure (MOPP) immediately after the Injection depending on










41.72 ± 9.74 26.81 ± 8.68
Ranibizumab
(0.07 mL)
45.15 ± 9.65 24.27 ± 8.51
p value > 0.05 > 0.05
Table 5 Intraocular Pressure (IOP) and Mean Ocular Perfusion
Pressure (MOPP) immediately after the Injection depending on









Yes 39.92 ± 9.12 28.83 ± 9.56
No 44.68 ± 9.27 24.48 ± 8.27
p value > 0.05 > 0.05
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In designing this study, it was predicted that the
stressful situation of intravitreal injection would increase
the MBP, resulting in an attenuation of the decrease in
MOPP. Evaluation of serial changes in MBP revealed
that pre-injection mean BP was 95.39 ± 9.16 mmHg and
mean MBP immediately after the injection, and at
30 min, 1 day, and 1 week after the injection was 104.28
± 8.92 mmHg, 95.93 ± 9.39 mmHg, 93.57 ± 8.54 mmHg,
94.27 ± 7.48 mmHg, respectively. Compared to the pre-
injection MBP, MBP immediately after the injection in-
creased by 9 mmHg, equivalent to the 6 mmHg increase
in MOPP. Consequently, the rise in MBP right after the
intravitreal Avastin or Lucentis injection can be consid-
ered to have a protective effect against the decrease in
post-injection MOPP.
A previous report by Rasier et al. revealed an increase
in blood pressure, which was checked 1 week, 3 weeks,
and 6 weeks after intravitreal Avastin injection [15].
Rasier et al. also warned of the possible occurrence of
systemic hypertension, which can be considered a sys-
temic complication following intravitreal Avastin injec-
tion [15]. In the present study, however, there was no
prominent increase in MBP during the 1 week following
intravitreal Avastin or Lucentis injection except for the
transient spike in MBP immediately after the injection.
Additionally, the type of injected drug (Avastin versus
Lucentis) did not have a statistically remarkable influ-
ence on the difference in MBP (p > 0.05).
Conclusion
In conclusion, Most eyes in our study achieved
normalization of IOP and MOPP within 30 min with-
out need for any immediate intervention, such as para-
centesis. Additionally, the decrease in MOPP caused by
the increase in IOP did not induce an extremely low
pressure level (< 10 mmHg). Based on these findings,
the instant increase in IOP after intravitreal anti-VEGF
injection does not cause a significant decrease in the
blood flow of the retina and optic nerve head. There-
fore, except for patients with glaucoma, uveitis, which
can cause impaired ability of IOP regulation, repeated
or prolonged IOP monitoring for normalization of IOP
after intravitreal anti-VEGF injections is not necessary.
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